SANTA CLARA, California, Sept. 9 [Category: BizLaboratory Sciences] -- Agilent Technologies, a company that specializes in life sciences, diagnostics and applied chemical markets, issued the following news release: * * * Agilent Refurbishment Centers Achieve Top-Level My Green Lab Certification * Agilent Technologies Inc. (NYSE: A) today announced that its Refurbishment Centers in Delaware, USA, and Singapore have achieved the highest level of My Green Lab Certification --Green level-- an in more PR

WILMINGTON, Delaware, Sept. 9 -- DuPont issued the following news release on Sept. 8, 2025: * * * Dawnsens New-Materials Co. Voluntarily Consents to Order Prohibiting the Importation of Flashspun Nonwoven Materials into the United States DuPont (NYSE:DD) today announced that the International Trade Commission (ITC) approved Dawnsens New-Materials Co. ("Dangs") voluntary agreement to a consent order which excludes Dangs from selling and importing into the United States all accused materials an more PR

DELAWARE, Ohio, Sept. 12 -- Ohio Wesleyan University issued the following news release on Sept. 11, 2025: * * * 'Thunder in the Valley' Civil War Expert to Discuss the Shenandoah Valley Campaign on Sept. 29 at Ohio Wesleyan * In August 1864, Union morale about the Civil War was so low that Republican Party leaders, including Abraham Lincoln, believed he would lose the November presidential election. Only dramatic turnaround victories on the battlefields could change that outcome. In his le more PR

DELAWARE, Ohio, Sept. 10 -- Ohio Wesleyan University issued the following news release on Sept. 9, 2025: * * * International Assistance Ohio Wesleyan Alumna Claire Everhart to Discuss 'The Case for Foreign Aid' on Sept. 24 * Claire Everhart, managing director of partnerships for the U.S. International Development Finance Corporation, will discuss "The Case for Foreign Aid" when she presents Ohio Wesleyan University's 2025 Corinne Lyman Lecture on International Studies. A 2010 OWU graduate, more PR

WILMINGTON, Delaware, Sept. 9 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * TAGRISSO (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer FLAURA2 final overall survival analysis reinforces thefavorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line standard of care and backbone ther more PR